Tyra Biosciences (TYRA) Projected to Post Quarterly Earnings on Tuesday

Tyra Biosciences (NASDAQ:TYRA) will likely be announcing its earnings results before the market opens on Tuesday, March 18th. Analysts expect the company to announce earnings of ($0.48) per share for the quarter.

Tyra Biosciences Stock Up 7.1 %

Shares of TYRA stock opened at $11.50 on Friday. The stock has a market capitalization of $581.93 million, a PE ratio of -7.14 and a beta of 1.09. Tyra Biosciences has a 52-week low of $9.93 and a 52-week high of $29.60. The stock’s 50-day moving average price is $13.55 and its 200 day moving average price is $17.11.

Insider Transactions at Tyra Biosciences

In related news, Director Nina S. Kjellson sold 3,993 shares of the company’s stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $16.36, for a total value of $65,325.48. Following the sale, the director now owns 3,707,420 shares of the company’s stock, valued at approximately $60,653,391.20. This represents a 0.11 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders have sold 21,998 shares of company stock valued at $344,818 in the last quarter. 15.40% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

TYRA has been the topic of several recent research reports. UBS Group initiated coverage on Tyra Biosciences in a research report on Tuesday, January 7th. They issued a “buy” rating and a $28.00 price target on the stock. HC Wainwright reiterated a “buy” rating and set a $30.00 target price on shares of Tyra Biosciences in a research report on Tuesday, February 18th. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and an average target price of $30.50.

Tyra Biosciences Company Profile

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.